Celldex presents data further supporting barzolvolimab clinical benefit in CSU

Celldex Therapeutics announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the company’s Phase 2 clinical trial in chronic spontaneous urticaria. Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face, hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 compared to placebo across multiple dose groups and demonstrated a favorable safety profile. The data presented further support these results by demonstrating improvements in AAS7 and additional measures of angioedema control. “The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,” said Diane C. Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. “Consistent with previously reported clinical outcomes, we observed rapid, durable and significant angioedema relief, including in omalizumab refractory disease. These data continue to support barzolvolimab’s potential to become a transformative treatment option for CSU and we look forward to moving closer to this goal with the initiation of our Phase 3 studies this summer.”